Professor of Medicine, Massachusetts General Hospital

Internal Medicine

Kenneth Freedberg practices Internal Medicine. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He over the years received 1 awards: "Elected Member". Kenneth Freedberg is a published doctor. He has 102 publications published. The most current publication "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States."

Publications

---

• Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.
• The Lifetime Medical Cost Savings From Preventing HIV in the United States.
• The clinical role and cost-effectiveness of long-acting antiretroviral therapy.
• The cost-effectiveness of genotype testing for primary resistance in Brazil.
• Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
• HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years.
• The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis.
• The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa.
• HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care?
• Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival.
• Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa.
• Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: A model-based analysis in Côte d'Ivoire.
• The survival benefits of antiretroviral therapy in South Africa.
• The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
• Diagnostic point-of-care tests in resource-limited settings.
• Incidence of WHO Stage 3 and 4 Events, Tuberculosis, and Mortality in Untreated, HIV-Infected Children Enrolling in Care Before 1 Year of Age: An Iedea (International ...
• Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
• Risk Factors for Late-Stage HIV Disease Presentation at Initial HIV Diagnosis in Durban, South Africa.
• Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe.
• Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
• Resistance in Pediatric Patients Experiencing Virologic Failure with First- and Second-Line Antiretroviral Therapy.
• Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
• The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
• Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
• Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
• The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
• Not All Are Lost: Interrupted Laboratory Monitoring, Early Death, and Loss to Follow-Up (LTFU) in a Large South African Treatment Program.
• Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa.
• What Will It Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis.
• Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa.
• Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire.
• Early infant HIV-1 diagnosis programs in resource limited settings: opportunities for improved outcomes and more cost-effective interventions.
• Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States.
• Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.
• Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.
• Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.
• Economic evaluation of ART in resource-limited countries.
• Predicting virologic failure in an HIV clinic.
• Frequent HIV testing among participants of a routine HIV testing program.
• Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
• Routine HIV screening in France: clinical impact and cost-effectiveness.
• The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa.
• Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire.
• Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuati...
• HIV/AIDS, undernutrition, and food insecurity.
• Improving outcomes in state AIDS drug assistance programs.
• HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies.
• Loss to care and death before antiretroviral therapy in Durban, South Africa.
• HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
• Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.
• Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.
• Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
• Cost-effectiveness of HIV testing and treatment in the United States.
• The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
• Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
• Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department.
• The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men.
• Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa".
• Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
• Visual screening for malignant melanoma: a cost-effectiveness analysis.
• Predictors of antiretroviral treatment failure in an urban HIV clinic.
• Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
• Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients.
• Optimizing resource allocation in United States AIDS drug assistance programs.
• The lifetime cost of current human immunodeficiency virus care in the United States.
• Implementing a routine, voluntary HIV testing program in a Massachusetts county prison.
• Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
• CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment.
• The survival benefits of AIDS treatment in the United States.
• Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
• Assessing the impact of federal HIV prevention spending on HIV testing and awareness.
• The private side of the professional man.
• Therapeutic drug monitoring in HIV treatment: a literature review.
• Refusing HIV testing in an urgent care setting: results from the "Think HIV" program.
• Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.
• Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
• Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral.
• Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.
• Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
• Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts.
• Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment.
• Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV.
• Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
• Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview.
• Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems.
• Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire.
• Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center.
• Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
• Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection.
• Utilities derived from visual analog scale scores in patients with HIV/AIDS.
• Discontinuation from HIV medical care: squandering treatment opportunities.
• Alcohol consumption and HIV disease progression: are they related?
• Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa.
• Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
• AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.
• Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.
• The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality.
• State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
• Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
• Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing.
• The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Schools

---

• Harvard Medical School

• Beth Israel Hospital

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Awards

---

• Elected Member

Education

---

• Beth Israel Deaconess Medical Center
• Harvard Medical School

Hospital

---

• Massachusetts General Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Natasha M. Archer, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen A. McCullough, MD
	Dr. Amanda K. Davis, MD This Doctor is OpenDoctor Recommended.
	Dr. Kevin L. Steiner, MD This Doctor is OpenDoctor Recommended.
	Dr. Manida Wungjiranirun, MD
	Dr. Mark K. Tuttle, MD
	Dr. Katherine C. Dallow, MD This Doctor is OpenDoctor Recommended.
	Dr. Vivek H. Murthy, MD This Doctor is OpenDoctor Recommended.
	Dr. Ami Shah, MD
	Dr. Patrick C. Dickerson, MD
	Dr. Geren S. Stone, MD This Doctor is OpenDoctor Recommended.
	Dr. Pooja R. Chitneni, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog